Skip to content
DataLookout
Menu

OPTIMANCT05394116

A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)

StatusActive, Not Recruiting
PhasePhase 3
Primary completion

At risk: Primary endpoint(s) modified.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 24 versions: 22 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Results posted: Nov 17, 2026
    • Primary endpoint(s) modified
    • Eligibility criteria shortened, about 4 words
    • Secondary endpoints: 16 to 23
  2. Minor Primary completion date changed from estimate of Jul 31, 2025 to Jul 17, 2025v21
  3. Notable Eligibility criteria revised
    • Primary completion date: Aug 4, 2025 to Jul 31, 2025
    • Study completion date: Sep 25, 2026 to Feb 27, 2029
    v20
  4. Notable Primary endpoints revised (2)
    • Primary completion date: Jul 31, 2025 to Aug 4, 2025
    • Study completion date: Oct 2, 2026 to Sep 25, 2026
    • Secondary endpoints revised (16)
    v19
  5. Minor Trial status: Recruiting to Active, Not Recruitingv18 Show 4 more changesShow less
    • Enrollment target: estimated 66 to confirmed 63
    • Study sites: 23 to 22
    • Primary completion date: Apr 10, 2025 to Jul 31, 2025
    • Study completion date: Jun 12, 2026 to Oct 2, 2026
Show 16 earlier versionsHide 16 earlier versions
  1. Minor Secondary endpoints revised (16)
    • Site details revised at 1 of 23 sites
    v17
  2. Minor Study sites: 22 to 23
    • Eligibility criteria revised
    v16
  3. Minor Study sites: 20 to 22v15
  4. Minor Study sites: 17 to 20v14
  5. Notable Primary endpoints revised (2)v13 Show 4 more changesShow less
    • Eligibility criteria expanded, about 1 word
    • Study completion date: Apr 10, 2026 to Jun 12, 2026
    • Secondary endpoints revised (16)
    • Study title expanded, about 2 words
  6. Minor Study sites: 16 to 17v12
  7. Minor Study sites: 9 to 16v11
  8. Minor Study sites: 8 to 9v10
  9. Minor Study sites: 7 to 8v9
  10. Minor Study sites: 6 to 7v8
  11. Minor Study sites: 4 to 6v7
  12. Minor Study sites: 2 to 4
    • Primary completion date: Mar 5, 2025 to Apr 10, 2025
    • Study completion date: Mar 5, 2026 to Apr 10, 2026
    v6
  13. Minor Study sites: 1 to 2v5
  14. Notable Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v4
  15. Notable Start date: Sep 29, 2022 to Nov 21, 2022v3 Show 4 more changesShow less
    • Eligibility criteria shortened, about 2 words
    • Study sites: 0 to 1
    • Primary completion date: Mar 8, 2025 to Mar 5, 2025
    • Study completion date: Mar 8, 2025 to Mar 5, 2026
  16. Notable Start date: Jul 14, 2022 to Sep 29, 2022
    • Study completion date: Mar 8, 2026 to Mar 8, 2025
    • Secondary endpoints: 15 to 16
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Number of New Heterotopic Ossification (HO) Lesions
Timeframe: Week 56
Number of Participants With Treatment-emergent (TE) Adverse Events of Special Interest (AESIs)
Timeframe: Baseline up to Week 56 [to include participants who discontinued earlier]

Secondary (20)

Number of Clinician-assessed Flare-ups
Number of Participants With New HO Lesions at Weeks 28 and 56
Total Volume of New HO Lesions
Percentage of Participants With Participant-reported Flare-ups
Number of New HO Lesions
Show 15 moreShow less
Percentage of Participants With Clinician-assessed Flare-ups
Number of Participant-reported Flare-ups
Change From Baseline in Joint Function Assessment by Physician Using Cumulative Analog Joint Involvement Scale (CAJIS)
Change in Pulmonary Function (Forced Expiratory Volume in 1 Second [FEV1]) as Assessed by Spirometry
Change From Baseline in Disease Severity as Assessed by the Patient Global Impression of Severity (PGIS)
Patient's Global Impression of Change (PGIC) Scale Score
Clinician's Global Impression of Change (CGIC) Scale Score
Concentration of Total Activin A in Serum Over Time
Concentration of Garetosmab in Serum Over Time
Number of Participants With Anti-drug Antibodies (ADA) to Garetosmab Over Time
Number of Participants With Titer Values of ADA to Garetosmab Over Time Through Week 56
Number of Clinician-assessed Flare-ups at Week 84
Percentage of Participants With New HO Lesions at Week 84
Change in Pulmonary Function (Forced Vital Capacity (FVC)) as Assessed by Spirometry
Change in Pulmonary Function (FEV1/FVC) as Assessed by Spirometry

Arms and interventions

High dose GaretosmabExperimental

Garetosmab is administered by intravenous (IV) administration every 4 weeks (Q4W)

Low dose GaretosmabExperimental

Garetosmab is administered by IV administration Q4W

PlaceboExperimental

Placebo to match garetosmab, is supplied as a liquid solution without the monoclonal antibody (or the protein) and is administered IV Q4W.

Drugs: Garetosmab, Placebo

Sites

22 sites in 18 countries

Japan 3, France 2, United States 2, Australia 1, Brazil 1, Chile 1, China 1, Colombia 1, Finland 1, Hong Kong 1, Italy 1, Malaysia 1, Netherlands 1, Poland 1, South Africa 1, South Korea 1, Spain 1, United Kingdom 1